Enterprise Value

1.974B

Cash

936.9M

Avg Qtr Burn

-103.2M

Short % of Float

8.53%

Insider Ownership

13.68%

Institutional Own.

84.44%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DNL310 (ETV:IDS) Details
Hunter syndrome MPS II

Phase 2/3

Data readout

DNL343 (eIF2B Activator) Details
Amyotrophic lateral sclerosis

Phase 2/3

Data readout

Phase 2b

Data readout

DNL758 (CNS-penetrant RIPK1 inhibitor) Details
Lupus nephritis, Cutaneous lupus erythematosus, Ulcerative colitis

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

TAK-594/DNL593 (PTV:PGRN) Details
Frontotemporal dementia with GRN mutations

Phase 1/2

Data readout

DNL126 (ETV:SGSH) Details
Sanfilippo Syndrome

Phase 1/2

Data readout